<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386097</url>
  </required_header>
  <id_info>
    <org_study_id>DiabetesIC2</org_study_id>
    <nct_id>NCT03386097</nct_id>
  </id_info>
  <brief_title>Interstitial Fluid in the Development of Cardiovascular Disease</brief_title>
  <official_title>Studies of the Importance of Interstitial Fluid in the Development of Cardiovascular Disease, an Expanded Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At a given level of serum cholesterol, patients with T2D have an increased risk of developing
      atherosclerosis compared with nondiabetic subjects.

      In a previous study we showed that the interstitial fluid-to-serum gradient of LDL and VLDL
      cholesterol is reduced in T2D patients compared with healthy controls. This was not found for
      HDL cholesterol. However, the cholesterol transporting function of HDL particles from
      interstitial fluid from patients with T2D were lower than in healthy controls. We hypothesize
      that that the apo B-containing particles in T2D patients are more susceptible to be retained
      or consumed in the extravascular space.

      We are to study if skin biopsies from T2D patients contain more cholesterol than biopsies
      from healthy controls. We hypothesize that samples from T2D patients are richer in
      cholesterol, which could explain why VLDL and LDL cholesterol are lower in relation to their
      plasma levels in T2D.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Interstitial fluid-to-serum ratio for LDL cholesterol</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cholesterol level in skin biopsies</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Type 2 diabetes patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of interstitial fluid, skin biopsies and blood</intervention_name>
    <description>Collection of interstitial fluid, skin biopsies and blood</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Type 2 diabetes patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Interstitial fluid, skin biopsies and blood (serum, plasma and whole blood)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy controls and type 2 diabetes patients over 18 years old, matched for age and
        gender.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Over 18 years.

          -  For the T2D study group: Diagnosed with type 2 diabetes.

        Exclusion criteria:

        For subjects with type 2 diabetes:

          -  Systemic inflammatory disease that requires active treatment

          -  Thyroid disease that requires active treatment

          -  Skin disease that requires active treatment and causes significant changes in the area
             of the skin that is to be investigated

          -  Treatment with oral glucocorticoids

          -  Levels of SR, TSH, T4 or Hemoglobin in the blood pronouncedly outside the reference
             range

          -  Pregnancy

        For healthy controls:

          -  Registered disease in the health declaration that requires continuous systemic
             treatment. Exception to the above: well controlled hypertension in which case the
             subject should not have treatment with more than one antihypertensive drug, the drug
             must not be an alpha-blocker or beta-blocker or thiazide diuretic

          -  Skin disease that requires active treatment and causes significant changes in the area
             of the skin that is to be investigated

          -  Blood pressure pronouncedly above 140/90

          -  Blood test results pronouncedly outside the reference range

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Rudling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mats Rudling</last_name>
    <phone>+46 8585 869 55</phone>
    <email>mats.rudling@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ekerö Vårdcentral</name>
      <address>
        <city>Ekerö</city>
        <state>Ekerö Kommun</state>
        <zip>17831</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viveca Åberg</last_name>
      <email>viveca.aberg@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Patient research centre, Clinic of endocrinology, Karolinska University Hospital</name>
      <address>
        <city>Huddinge</city>
        <state>Stockholm</state>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viveca Åberg</last_name>
      <email>viveca.aberg@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stiftelsen Stockholms Sjukhems Husläkarmottagning</name>
      <address>
        <city>Stockholm</city>
        <zip>11219</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viveca Åberg</last_name>
      <email>viveca.aberg@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GIH (gymnastik och idrottshögskolan)</name>
      <address>
        <city>Stockholm</city>
        <zip>11433</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Andersson</last_name>
      <phone>0046(0)739460034</phone>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>April 17, 2019</last_update_submitted>
  <last_update_submitted_qc>April 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Mats Rudling</investigator_full_name>
    <investigator_title>Professor, MD</investigator_title>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>Interstitial fluid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

